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Background
Tuberculosis (T) may be reactivated following a primary,
silent, and unknown T infection, when immunodefi-
ciency (often jatrogenic in origin), or other risk factors
(e.g. cancer, cachexia), become apparent. Post-primary
T episodes were described also decades after a primary
M. tuberculosis infection, in patients (p) who show
apparently limited radiographic signs at chest X-ray.
Some grade of immunodeficiency may also depend on
the administration of associated IFN-ribavirin for an
underlying chronic HCV hepatitis, as expressed by the
frequent emerging of leuko-neutropenia, and altered
cytokine network.
Methods
In a p aged >50 years with negative history of T, an
occasional chest X-ray showed fibrous-calcified infil-
trates at upper right lobe. After 11 years, due to a pro-
gressive chronic HCV hepatitis, pegylated IFN-ribavirin
were started for 7 months, until a sudden occurrence of
cough-hemoptisis associated with a pulmonary lesion
highly suggestive of T became apparent, in the same
area where some reliquates of a primary T were demon-
strated 11 years before.
Results
A HRCT examination pointed out 2 different excavated
infiltrates. Both direct microscropy and culture of spu-
tum-BAL proved positive for M. tuberculosis (susceptible
to all tested compounds), while Mantoux-Quantiferon
assays also tested positive. An absolute lymnphopenia
(nadir 966 cells/μL), prompted a T-cell subset study,
which showed an imbalance of the CD4/CD8 ratio (30/
45%), and an absolute CD4 count of 290 cells/μL. Not-
withstanding 7 consecutive weeks of isoniazide,
ethambutol, rifampicin and pyrazinamide administration,
sputum examination remained positive, thus confirming
the role of immunodeficiency is prompting a difficult-to-
treat T. The adjunct of levofloxacin-amikacin-linezolid
attained clinical-bacteriological cure, after 12 weeks.
Discussion
Waiting for human experimental data, two animal mod-
els demontrated that an increased release of immuno-
suppressive cytokines (IL-10-TGF-b), may prompt
T reactivation, while a maintained T-cell competence
enhances T latency. Although a few cases of non-infec-
tious lung involvement, interstitial pneumonia, and
bronchiolitis obliterans were described during IFN ther-
apy administered to transplant p, reactivated T was
excepional. The expected increase of therapeutic use of
IFN and potent agents for the management of chronic
hepatitis or other diseases, might support the reactiva-
tion of latent T. A careful medical history, Mantoux
reaction, IGRA testing, and a chest X-ray, are manda-
tory before starting IFN therapy. In fact, the jatrogenic
immunosuppression related to IFN-ribavirin may go
beyond the expected leuko-lymphopenia, and also act
against the quantitative-functional role of CD4 lympho-
cytes. This last circumstance may play a key role in
T reactivation, when T latency is of concern.
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